BioCentury | Oct 22, 2020
Politics, Policy & Law

Protecting biomedical innovation as a national security asset

In recent years, it has become fashionable to focus on the high price of new treatments for certain cancers and rare diseases. Many observers ask why it is that U.S. citizens should subsidize the rest...
BioCentury | Aug 7, 2020
Politics, Policy & Law

Latest executive order in spree to control biopharma centers on American-made drug products

An “America first” drug sourcing order signed Thursday is the latest in a series of attempts by President Donald Trump to bend the biopharma industry to his will in an effort to keep campaign promises...
BioCentury | Jul 10, 2020
Politics, Policy & Law

Democrats, Republicans could find common ground on drug pricing recommendations from Biden-Sanders task force

Recommendations from a task force assembled by Joe Biden and Sen. Bernie Sanders (I-Vt.) include several healthcare policies favored by Democrats, like Medicare drug price negotiation, but stop short of Medicare for All. The bulk...
BioCentury | Jul 10, 2020
Politics, Policy & Law

Four House committee bills seek to create tax benefits for biotechs developing infectious disease treatments

As the COVID-19 pandemic makes clear the need for innovative therapies to treat infectious diseases, a trio of Republicans on the House Ways and Means Committee introduced a series of bills offering tax benefits for...
BioCentury | Jul 6, 2020
Politics, Policy & Law

Trump to sign drug pricing order, chief of staff says

President Donald Trump will sign executive orders this week on drug pricing, bringing manufacturing back to the U.S., and immigration, White House Chief of Staff Mark Meadows said Monday in a television interview on Fox...
BioCentury | Jun 24, 2020
Product Development

Action needed to prevent manufacturing bottlenecks on COVID-19 therapies

Demand for COVID-19 therapies could far exceed supplies unless urgent steps are taken to prioritize and expand manufacturing capacity for the most promising therapeutic candidates, according to biopharma industry executives and public policy scholars. A...
BioCentury | Jun 6, 2020

Academic startups the most likely biotech beneficiaries from U.K. Future Fund

While VCs have broadly applauded the U.K. government for launching the £250 million Future Fund to provide financial aid to private companies hit by the pandemic, the size and structure of the fund makes it...
BioCentury | May 22, 2020
Politics, Policy & Law

Lawmakers propose tax credit for domestic manufacturing

As the U.S. seeks to secure its supply chain following global disruptions from the COVID-19 pandemic, two Republican lawmakers are backing legislation that would enact a tax incentive to encourage manufacturers to keep production domestic....
BioCentury | May 20, 2020

$145M raise positions Rallybio to bring first rare disease program into clinic

With its series A funds deployed to acquire three rare disease programs, Rallybio has raised a $145 million series B led by Pivotal bioVenture Partners to bring the first of those candidates into the clinic...
BioCentury | Apr 21, 2020
Politics, Policy & Law

BIA calls on U.K. to bolster £1B relief package by advancing R&D tax payments

The BioIndustry Association is calling on the U.K. government to advance payments from its R&D tax credit system to unlock five times the capital being offered under a new £1 billion ($1.2 billion) plan to...
Items per page:
1 - 10 of 1202